Introduction: The standard of therapy for some patients with coronary artery disease, particularly those who arrive with acute coronary syndrome, is percutaneous coronary intervention (PCI) (ACS). To avoid thrombotic problems during PCI, the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) advise using anticoagulation in addition to dual antiplatelet treatment (DAPT). Objective: to assess how enoxaparin affects the active clotting time (ACT) and how UFH reacts to enoxaparin. Material and methods: The intervention cardiology department at Hayatabad Hospital Complex in Peshawar did this crosssectional descriptive research from June 1 to April 30, 2022. By using a non-probability sequential sampling strategy, patients were included. After a thorough history, examination, and informed permission, all patients 18 years old having PCI were included in the research. Individuals with known blood dyscrasias or thrombophilia, as well as those who had received anticoagulation within the previous 12 hours or just prior, were excluded from the trial. Results: Among the patients who received heparin, ACT increased from 104.76±27.31 seconds to 448.34±169.11 (t-statistic=13.750, 95% CI: 293.9540 to 393.2060, p: <0.01) whereas among patients who received enoxaparin, this number increased from 99.58±27.68 seconds to 334.37±166.45 seconds (t statistic=6.817, 95% CI: 165.4597 to 304.1203, p:<0.01). The postanticoagulation ACT was significantly higher in the heparin group compared to enoxaparin group i.e. 448.34±169.11 and 334.37±166.45 seconds respectively (t statistic=2.700, 95% CI: 29.7639 to 198.1661, p:<0.01). Conclusion: After taking i.v. enoxaparin and heparin, the ACT is extended in patients for around 15 minutes, and this prolongation may help track the anticoagulant action of the medication. Moreover, in this situation, ACT levels and ENOX clotting times are correlated. A bigger experiment will be necessary to determine the association between ACT level and clinical effectiveness utilising intravenous enoxaparin.